177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study

By afschroeder • November 13, 2025

Kishan AU, Valle LF, Wilhalme H, Felix C, Nabong R, Juarez-Casillas JE, Flores K, Ma TM, Ludwig V, Nakayama M, Ells Z, Dahlbom M, Lauria M, Meyer C, Cao M, Weidhaas JB, Telesca D, McGreevy K, Nickols NG, Karasik D, Parmisano S, Basehart TV, Brisbane W, Marks L, Rettig MB, Reiter RE, Boutros PC, Allen-Auerbach M, Czernin J, Steinberg ML, Calais J. ¹⁷⁷Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study. J Clin Oncol. 2025 Nov 12:JCO2501553. doi: 10.1200/JCO-25-01553. Epub ahead of print. PMID: 41223345.

Tags: Cardiology/Epi, DOM STAT, General Internal Medicine, Hematology/Oncology, Publications, Veterans Administration

Related Posts

Air Pollution Triggers Metabolomic Signature of Mitochondrial Dysfunction in Mice and Humans: Implications for Cardiovascular Disease Development

Lin Y, Qiu X, Gupta R, Ramanathan G, Lu X, Yin F, Fiehn O, Zhang JJ, Kaufman JD, Zhu Y, Rosenfeld M, Araujo JA. Air[...]

Lamin B1 Coordinates the Assembly of the Nuclear Lamina

Kim JR, Kim PH, Tu Y, Carroll J, Koerner JP, Young SG, Fong LG. Lamin B1 Coordinates the Assembly of the Nuclear Lamina. J Cell[...]

Regulators of Mineralization and Long-Term Progression of Aortic Valve and Mitral Annular Calcification: MESA

Bortnick AE, Naveed M, Fu X, Shea K, Kestenbaum B, de Boer I, Ix JH, Kim R, Hamerton E, Kankaria R, Tracy RP, Tsai M,[...]